Patent Clock Ticks for LITFULO After FDA Review Period
Published Date: 5/12/2025
Notice
Summary
The FDA has officially set the review period for LITFULO, a human drug product, so its patent can be extended. This helps the drug maker get extra time to protect their invention after the long approval process. If you’re involved in drug patents or development, this means important timing updates and potential market exclusivity changes.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Patent Extension Eligibility Set
The FDA has determined the regulatory review period for the drug LITFULO so its patent can be extended. This lets the patent holder seek extra time to protect the invention after the drug approval process.
Timing and Exclusivity Updates for Developers
The notice provides timing updates related to LITFULO's regulatory review period and says there could be changes to the drug's market exclusivity. If you work on drug patents or development, this alerts you to important timing and exclusivity effects for LITFULO.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2025-08254 — Determination of Regulatory Review Period for Purposes of Patent Extension; JAYPIRCA
The FDA has officially set the review period for JAYPIRCA, a human drug product, so its patent can be extended. This means the company behind JAYPIRCA gets more time to protect their invention and potentially earn more money. Anyone interested in drug patents or new medicines should keep an eye on this important timing update.
Next: 2025-08256 — Determination of Regulatory Review Period for Purposes of Patent Extension; ELREXFIO
The FDA has officially set the review period for ELREXFIO, a new human biological product. This means the company behind ELREXFIO can apply to extend their patent, giving them more time to protect their invention. This helps the company keep their exclusive rights longer, potentially affecting when generic versions can enter the market.